Mental Health DailyResearch. Evidence. Perspective.Published research on antipsychotics.
A 2026 clinical-lab study tested a 77-drug liquid chromatography-tandem mass spectrometry serum screen in 1,021 patients and found that benzodiazepines accounted for 37.9% of all detections,…
Read articleA 2026 individual participant data meta-analysis of 1,721 dementia trial participants linked risperidone to cerebrovascular adverse events, HR 4.11 (95% CI 1.77 to 9.51), and major cardiovas…
Read articleMukai et al.’s 499-person Phase 2b schizophrenia trial tested whether higher, sustained PDE10A inhibition could turn MK-8189 into a non-D2 antipsychotic; it did not. At week 6, MK-8189 misse…
Read articleFirst-generation antipsychotic (FGA) shortages are not just pharmacy annoyances; they force medication changes in people who may have taken years to stabilize on a tolerable regimen. Researc…
Read articlePatients with schizophrenia have substantially elevated dementia risk compared to the general population — roughly 2-3 times the age-adjusted rate — but the specific drivers within the schiz…
Read articleClozapine is the only medication with proven efficacy for treatment-resistant schizophrenia, yet most eligible patients wait years before starting it. A 2026 paper by Perfalk and colleagues …
Read articleLurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysi…
Read article
